|
|
 |
|
Viewing report
|
|
|
|
The CNS Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Business Insights, Sep 2008, Pages: 231
'The global CNS disorders market expanded by 8.0% from 2006, to reach total sales of $77.3bn in 2007. This growth has been primarily driven by treatments for AD, ADHD and Parkinson’s Disease.'
The CNS disorders market is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms continue to be favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs. High levels of investment have contributed to a rich product pipeline, with an estimated 600 clinical candidates currently under development, and companies are widely engaged in licensing novel/clinically differentiated CNS products.
The sector has struggled recently however, with previously dominant product classes coming under increasing pressure from generic competition and safety concerns. ‘The CNS Market Outlook to 2013’ is a new report published by Business Insights that provides comprehensive coverage of the major markets within the global CNS disorders market, incorporating a detailed epidemiological analysis of major indications and key factors impacting their prevalence. This report profiles the factors and underlying trends shaping the market landscape and identifies the most promising areas of potential growth. Current leading brands of treatment within each indication are assessed and ten of the market’s leading players are profiled. Sales forecasts for currently marketed and key pipeline products over the 2008-13 period are also provided. Discover the key trends and growth drivers of the CNS market, assess the competitive dynamics of leading companies and evaluate the future prospects of pipeline products with this report...
‘The CNS Market Outlook to 2013’ is a report published by Business Insights that provides detailed coverage of the major markets within the global market for CNS disorder treatments, incorporating a detailed epidemiological analysis of major indications and the key factors impacting their prevalence. This report profiles the factors and underlying trends shaping the market landscape and identifies the most promising areas of potential growth. Current leading brands of treatment are assessed and ten of the market’s leading players are profiled. Sales forecasts for currently marketed and key pipeline products to 2013 are also provided.
Assess the competitive dynamics of leading companies and evaluate the future prospects of pipeline products within the CNS disorders market...
Use this new report to...
“Despite being highly genericized, the CNS disorders market is dominated by the sales of original brands. These accounted for $53.5bn, representing 66.9% of the CNS market in 2007. Licensed brands and other brands recorded approximately the same market share of 10.7% and 9.2% respectively...“
- Assess epidemiology, treatment trends and sales patterns for treatment markets including depression, schizophrenia, AD, migraine, epilepsy, PD, insomnia and ADHD across major countries including the UK, Japan, France, Germany, Italy, Spain and
the US.
- Measure the market performance and strategic positioning of major CNS developers with this report’s evaluation of the franchises and market shares of AstraZeneca, Eli Lilly, Eisai, Forest, GSK, J&J, Novartis, Pfizer, Sanofi Aventis and Wyeth.
- Understand the market dynamics of the global CNS disorders area and identify the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.
- Predict revenues for major currently marketed and pipeline CNS products over 2008-13, with this report’s sales forecasts across major indications, treatment classes and company portfolios.
- Discover the strategies that offer the greatest success potential for CNS developers in the future and understand the challenges currently facing companies within this therapeutic area.
Some Key Findings from this Report
“The US market accounted for the bulk of global sales in 2007, with 59.0% or $46.4bn . Germany led the major EU markets with a global market share of 5%; equivalent to sales of $3.7bn for 2007. Italy made the smallest contribution of the seven major markets having achieved sales of $1.4bn in 2007...”
- The global CNS disorders market expanded by 8.0% from 2006, to reach total sales of $77.3bn in 2007. This growth has been primarily driven by treatments for AD, ADHD and Parkinson’s Disease.
- Schizophrenia treatments held the largest share of the CNS market with a share of 26.8%, following sales of $20.7bn in 2007. Atypical antipsychotic products dominate the schizophrenia market, having accrued sales of $19.8bn in 2007.
- The global anti-Alzheimer's market expanded by 21.3% between 2006-2007, to record total sales of $5.6bn. Steady growth will continue over 2007–2013 due to growing patient numbers and the increasing level of R&D investment in disease-modifying agents.
- Depression and insomnia were the only two CNS segments to experience falling sales over 2006–2007, declining by 4.5% and 8.5% respectively. Blockbuster patent expiries and the rise of generic competition have had a significant impact upon both markets.
- The ten leading companies represented 67.6% of the CNS disorders market in 2007. J&J currently leads the market with an 8.1% share, driven by Risperdal’s impressive growth in antipsychotics.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
The CNS Market Outlook to 2012
CNS Therapeutics - A World Market Review
CNS Therapeutics - A World Market Review
CNS Therapeutics - Global Strategic Business Report
The CNS Market Outlook to 2010
The CNS Market 2008 Report
The CNS Outlook to 2007
Commercial Insight: CNS Market Overview - Commercial Dynamics And Outlook Of The Neurology, Pain And Psychiatry Market Sectors
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntingtons Disease
CNS - Competitive Analysis, Profiles and Portfolio Strategies of CNS Therapeutic Manufacturers in the US, 2002
Drug Delivery Technology - Revolutionizing CNS Therapies
Pipeline Insight: Orphan Diseases in CNS - Part II: Amyotrophic Lateral Sclerosis
|
|
|
|
